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Purpose: Type 2 diabetes mellitus (T2DM) is a chronic and metabolic disorder affecting
large set of population of the world. To widen the scope of understanding of genetic
causes of this disease, we performed interactive and toxicogenomic based systems
biology study to find potential T2DM related genes after cDNA differential analysis.
Methods: From the list of 50-differential expressed genes (p < 0.05), we found
9-T2DM related genes using extensive data mapping. In our constructed gene-network,
T2DM-related differentially expressed seeder genes (9-genes) are found to interact with
functionally related gene signatures (31-genes). The genetic interaction network of both
T2DM-associated seeder as well as signature genes generally relates well with the
disease condition based on toxicogenomic and data curation.
Results: These networks showed significant enrichment of insulin signaling, insulin
secretion and other T2DM-related pathways including JAK-STAT, MAPK, TGF, Toll-like
receptor, p53 and mTOR, adipocytokine, FOXO, PPAR, P13-AKT, and triglyceride
metabolic pathways. We found some enriched pathways that are common in different
conditions. We recognized 11-signaling pathways as a connecting link between
gene signatures in insulin resistance and T2DM. Notably, in the drug-gene network,
the interacting genes showed significant overlap with 13-FDA approved and few
non-approved drugs. This study demonstrates the value of systems genetics for
identifying 18 potential genes associated with T2DM that are probable drug targets.
Conclusions: This integrative and network based approaches for finding variants in
genomic data expect to accelerate identification of new drug target molecules for different
diseases and can speed up drug discovery outcomes.
Keywords: T2DM, microarray dataset, gene signatures, pathways enrichment analysis, drug targets
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic and complex
disease that is characterized by hyperglycemia in the context
of insulin resistance and relative lack of insulin (Kumar et al.,
2005). Globally, it is estimated that there are more than 285
million people with T2DM making up about 90% of diabetes
cases (Melmed et al., 2011). The disease mechanism is known
to a considerable extent and tissues including pancreatic islets,
liver, skeletal muscle, adipose tissues, gut, and the immune system
play a role in its progression (Kolb and Eizirik, 2011). Although
several key factors including lifestyle, diet, obesity and genetic
shave been recognized in the progression of insulin resistance
and T2DM (Polonsky et al., 1996; Florez, 2008; Ripsin et al.,
2009), the underlying mechanisms remain unclear. It has become
a progressively challenging health issue due to its high morbidity,
mortality, and heightened incidence worldwide (Melmed et al.,
2011).
Recent advances revealed that diabetes is a heterogeneous-
disease with complex genetic mechanisms. Several biological
systems seem to be connected in the progression and
development of T2DM; however the limited understanding
of the complications of these systems and their interactions
has been a major obstruction in the progress of optimal
treatments in T2DM. Most cases of diabetes involve many
genes, with each being a minor contributor to an intensified
possibility of becoming a type 2 diabetic (Melmed et al.,
2011) and similarly genes connected with T2DM poorly
signify established pathways of insulin signaling (Florez,
2008). The existing methods to find statistically significant
functional classes in T2DM related genes have recognized
enrichment of cell cycle regulation (McCarthy, 2010;
Voight et al., 2010). Nonetheless, the functional categories
and therapeutic role of the expressed genes in T2DM and
molecular biology of insulin resistance has not been completely
understood (Voight et al., 2010). Therefore, significant
gaps in clinical outcome still remain within each of these
problems, leading investigators to continue searching for more
improvement.
Differential expression in islets from diabetic and control
individuals explored the list of genes related to type 2
diabetes mellitus. Among the list of probable genes, CHL1,
LRFN2, RASGRP1, and PPM1K were significantly associated
with insulin secretion and diabetes type 2. During this
global expression analysis, it was found that fifty genetic loci
associated with T2DM due to genetic co-expression and protein-
protein interaction involved in insulin secretion and HbA1c
(Taneera et al., 2012). It has been observed that the effect
of genetic variations on incessant glycemic events in non-
diabetic individuals primarily reveal perturbation of insulin
secretion (Jain et al., 2013). Another systems biology approach
based on genome wide association studies explored the T2DM
pathophysiology and insulin signaling genes (Jain et al., 2013).
Similarly, the abnormal secretion of glucagon led to islet
inflammation in T2DM and it has been seen the interleukin-
6 is involved to stimulate the glucagon secretion (Chow et al.,
2014).
Genomic expressions in insulin signaling and integrated
pathways may manifest themselves and to interrupt any
one of these genes could develop the clinically significant
insulin resistance and diabetes (Melmed et al., 2011). The
systems biology approach potentially integrate these biological
networks and will help in revealing key elements involved in
pathogenesis. As genetic expression is vital to better understand
the network of systems biology, thereby cDNA microarray
technology is a valuable tool for analyzing expression levels
of thousands of genes at the same time. The large number
of expression datasets in the public domain provides a rich
source for genome-wide information on T2DM and affords an
opportunity to do expression study with a large number of
samples.
Therefore, we executed differential analysis to show the target
gene signatures associated with insulin resistance and T2DM.
In particular, by probing microarray data, we attempted to find
a statistically significant T2DM-related differentially expressed
genes in diabetic tissue compared to normal. In our study,
we constructed the metabolic pathways to uncover new drug
targets. We began the analysis by aiming on insulin-signaling
and associated cellular genes, a natural and well-established
candidates for finding a signature set of genes (Taniquchi
et al., 2006) associated with insulin resistance or diabetes.
The framework established in this paper is designed to focus
key questions: (1) Can biological processes be recognized that
are deregulated in metabolic pathways of insulin resistance
and diabetes (2) can genetic interaction networks be helpful
to reveal new drug targets and biomarkers for optimizing
the treatment strategies. Studying these molecular networks
from the prospective of probing new drug targets can deliver
valuable insights in both biological and medical research. The
comprehensive illustration of our study framework has been
shown in Figure 1.
MATERIALS AND METHODS
Source Data
The aim of this study was to find new drug target gene
signatures associated with insulin resistance and T2DM. The
study design of this dataset indicated to extract RNA from
the vastus lateralis of normal (NGT), glucose intolerant
(IGT) and type 2 diabetic individuals (total: 118 samples).
Our analyses in this study restricted to genes commonly
covered by hgu133plus2 chips. We accessed the source
expression data for the AffymetrixHG-U133_Plus_2 microarray
GSE18732 (Gallagher et al., 2010) from Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE18732). The GPL9486 Affymetrix GeneChipHuman
Genome U133 Plus 2.0 Array (CDF: Hs133P_Hs_ENST,
version 10) (Affymetrix, Inc., Santa Clara, CA, 95051, USA,
Technology: in situ oligonucleotide) platform was used, and
the annotation information (hgu133plus2) of probes was
used to detect the gene expression. We used computational
analysis using R (http://www.r-project.org) and BioConductor
(http://www.bioconductor.org) packages.
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FIGURE 1 | The comprehensive and squential steps in our study design.
Normalization and Differential Expression
Analysis
We organized the pheno-data files of this dataset in recognizable
format (Troyanskaya et al., 2001). The data was normalized to
the median expression level of each gene using the bioconductor
“ArrayQuality Metrics” package (Bolstad et al., 2003; Fujita et al.,
2006; Obenchain et al., 2014). The expression of a transcript
with detection p-value 0.15 was considered marginal. We log
transformed and quantile normalized the arrays to make sure
that they were on the same scale, and computed the gene-
gene covariance matrix across all arrays (54675 affyids), ignoring
missing values. In order to get a summary of intensities, the
Robust Multi-array Analysis (RMA) was used to correct the
background (Troyanskaya et al., 2001) for perfect matches (PM)
and mismatches (MM). We used the RMA-algorithm to calculate
averages between probes in a probe set. To measure the quality
of RNA in these samples, AffyRNAdeg, summaryAffyRNAdeg,
and plotAffyRNAdeg packages was used for degradation analysis
(Affymetrix, 1999, 2001). We performed relative study and
identified differentially expressed genes by pair wise comparison
from genomic experiments (Tusher et al., 2001) and multiple
testing corrections were completed by Benjamini-Hochberg
method (Benjamini and Hochberg, 1995). The Limma package, a
modified statistic that is proportional to the statistic with sample
variance-offsets, was used to shortlist the DEGs and duplicate
spots and quality weights were measured. The moderated
statistics were calculated; genes were prioritized with respect to
the resulting scores and p-values. A false discovery rate (FDR)
less than 0.05, p ≤ 0.05, Average Expression Level (AEL) ≥40%
and an absolute log fold change (logFC) greater than 1 were set as
the significant cutoffs (Jin and Da, 2013).
K-Fold Validation
We employed K-Fold study of cross-validation and bootstrap for
accuracy estimation in differential analysis (Seymour, 1993). The
advantage of this method is that all the samples in the dataset are
eventually used for both training and testing. K-fold technique
is generally better for determining approximate average error
and it was used to validate the shortlisted differentially expressed
genes using the bioconductor “boot” package. Boots trapping is
successfully being used to correct biases in analysis (Ripley, 2010).
We applied the generalized linear Gaussian models and used the
“cv.glm” function to assess the k-fold cross validation for these
cases. The true error is estimated as the average error rate:
E = 1/K
K∑
i = K
Ei (1)
The Gaussian function was trailed by the Leave-One-Out-
Cross-Validation (LOOCV) procedure. The LOOCV method
is intuitively termed as one is left out as the testing-set and
remaining data are used as the training-set (Ripley, 2010). For
each experiment, we used N-1 subsets for training and the
remaining for testing. The true error is estimated as the average
error rate on test cases:
E = 1/N
N∑
i = K
Ei (2)
By increasing the number of folds, the bias of the true error rate
estimator will be small and correct (Richard and Dennis, 1984;
MAQC Consortium, 2010).
Disease-Gene Interaction and Cluster
Analysis
Biomedical text mining system is useful to extract specific
information from the literature based on the interactions among
different types of biomedical entities (Clematide and Rinaldi,
2012). So, from the list of shortlisted DEGs, we investigated
the insulin resistance and T2DM associated genes using diverse
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FIGURE 2 | Normalization and analysis of array quality metrics shows a color heatmap of the distances between arrays. The color scale is chosen to
cover the range of distances encountered in the dataset. Patterns in this plot can indicate clustering of the arrays either because of intended biological or unintended
experimental factors (batch effects). The distance dab between two arrays a and b is computed as the mean absolute difference (L1-distance) between the data of the
arrays (using the data from all probes without filtering). In formula, dab = mean | Mai - Mbi |, where Mai is the value of the i-th probe on the a-th array. Outlier detection
was performed by looking for arrays for which the sum of the distances to all other arrays, Sa = 6b dab was exceptionally large. 12 such arrays were detected, and
they are marked by an asterisk, *.
data sources including CTD (Comparative Toxicogenomics
Database) (http://ctdbase.org/), PubMed (http://www.ncbi.nlm.
nih.gov/pubmed), OMIM (Online Mendelian Inheritance in
Man) (http://www.ncbi.nlm.nih.gov/omim), MeSH (http://www.
ncbi.nlm.nih.gov/mesh) and PMC (http://www.ncbi.nlm.nih.
gov/pmc) database to filter disease specific genes.
We performed the Absolute Pearson correlation cluster
analysis (Eisen et al., 1998) based on expression values in
each sample of T2DM-associated differential expressed genes to
explore expression profiling and biological functions (Nam and
Kim, 2008) using the CIMminer tool (Scherf et al., 2000).
Gene Network Analysis and Identifying
Gene Signatures
Proteins usually interact with each other to carry out biological
functions (Li et al., 2004; Muhammad et al., 2014) and therefore
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FIGURE 3 | Side-by-side plot produced by plotAffyRNAdeg
representing 5′ to 3′ trendpresenting an assessment of the severity of
degradation and significance level.
gene network aims to find biological processes that are steadily
deregulated across a cDNA data related with disease conditions
in human tissues. In PPI network, each protein is considered as
belonging to one or more gene-sets connected with biological or
molecular functions (Rachlin et al., 2006). The normal function
of these biological networks may show much altered activity in
the disease state compared to normal.
To overview the global network of DEGs of microarray
dataset, genes in the connection groups were retrieved with
a high confidence score (0.999) in the STRING (Search Tool
for the Retrieval of Interacting Genes/Proteins) version 10
(Szklarczyk et al., 2011) and HAPPI (Human Annotated and
Predicted Protein Interaction) databases (Chen et al., 2009)
for protein-protein interactions. These databases mines and
annotate comprehensive physical and genetic mapping described
in the primary peer-reviewed literature and includes the data
that is validated by experimental studies in an inclusive
form to support simulation analysis of biological networks
and estimation of gene/protein functions. We used Cytoscape
software (version 3.2.1) to visualize and analyze molecular and
interaction networks (Cline et al., 2007). In this network, we
determined the role of each gene signatures (target genes) in
type 2 diabetes mellitus that interacted with T2DM-related seeder
genes (source genes) by gene mapping using CTD, PubMed,
OMIM, MeSH and PMC databases. The motivation for gene-
mapping in the network is to find potentially T2DM-related-
gene signatures is the hypothesis that genes whose dysfunction
contributes to a disease phenotype tend to be functionally related.
The total number of gene signatures associated with each seeder
protein was measured. We assembled the gene signature that
are associated with pathways of interest leading to T2DM and
TABLE 1 | k-fold cross validation by bioconductor “boot” package using
Gaussian dispersion parameters.
Estimate Std. error t. value Pr(>|t|)
(Intercept) 0.038148 0.004451 8.57 <2.00E-16***
x1 0.155175 0.005914 26.239 <2.00E-16***
x2 −0.03757 0.00669 −5.617 <1.96E-08***
x3 0.159384 0.004926 32.357 <2.00E-16***
x4 0.157941 0.005739 27.522 <2.00E-16***
x5 0.149692 0.005343 28.015 <2.00E-16***
x6 0.124573 0.005183 24.034 <2.00E-16***
x7 −0.08823 0.002789 −31.636 <2.00E-16***
x8 0.130695 0.006101 21.422 <2.00E-16***
x9 0.428922 0.004996 85.849 <2.00E-16***
x10 0.040628 0.004818 8.433 <2.00E-16***
x11 0.132742 0.005614 23.645 <2.00E-16***
x12 −0.01105 0.005375 −2.055 0.0399*
x13 −0.27454 0.005962 −46.052 <2.00E-16***
x14 0.044612 0.005961 7.484 7.29E-14***
x15 −0.11979 0.006822 −17.561 <2.00E-16***
Deviance Residuals: Min (−2.6702), 1Q (−0.1516), Median (−0.0100), 3Q (0.1431), Max
(4.9980).
Signif. codes: 0 “***” 0.001 “**” 0.01 “*” 0.05 “.” 0.1 “” 1.
Number of Fisher Scoring iterations: 2; $K: [1] 10; $delta: [1] 0.08847 = 0.08846.
Null deviance: 171914.5 on 54674 degrees of freedom.
Residual deviance: 4827.2 on 54659 degrees of freedom.
constructed a molecular sub-network of these genes that are
highly transcriptionally affected in the diabetes state. We used
Network Analyzer in Cytoscape to calculate topological network
properties. Nodes in the network were categorized according
to the degree of association of gene signature with T2DM.
Gene ontology (GO) enrichment of the network help us to
show biological functions (Nam and Kim, 2008; Muhammad
et al., 2015), and it was carried out using the web-based
DAVID (Database for Annotation Visualization and Integrated
Discovery) (Huang et al., 2009) and FunRich Annotation tools
(Pathan et al., 2015). For these set of gene signatures, p-value
and FDR were assigned to the number of conditions where
it is enriched. The gene-sets with a substantial p-value were
considered as transcriptionally affected in a wide range of
diabetes associated samples.
Prediction of Gene Signature Specific
MiRNA Targets
MiRNAs are considered as post-transcriptional regulators of a
large set of genes involving in many biological processes and
signaling pathways. So, a useful step for understanding their
functional role is characterizing their influence on the gene
targets that help us to understand the disease etiology (Alshalalfa
and Alhajj, 2013). Using miRNA influence as a functional
signature is promising to find molecular connotations between
miRNAs and related gene signatures. MiRNA targets of T2DM-
related gene signatures were determined by microRNA target
predictor (powered by miRanda, mirSVR) and structure duplex
sequences were predicted. MiRNA targets were selected based on
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FIGURE 4 | Type 2 diabetes mellitus specific differentially expressed
genes. These genes were curated using CTD (Comparative Toxicogenomics
Database), PubMed, OMIM (Online Mendelian Inheritance in Man), MeSH and
PMC databases.
the mirSVR score (<=−0.1) which is considered as “good” score
(Betel et al., 2008).
Integrated Genome-Scale Pathway
Reconstruction with Putative T2DM Linked
Genes
A major goal of systems biology is to reconstruct and model
in silico the metabolic networks of disease related genes. We
analyzed the integrated, interactive and metabolic network of
T2DM-related gene signatures and observed the correlation
between these pathways. Cellular and signaling pathways
were reconstructed from the combined gene signatures using
PathVisio 3tool (Kutmon et al., 2015). These genes were
mapped and curated using KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathways on the basis of literature and
database evidence. KEGG, a public domain database generally
used for gene-enrichment analysis and pathway visualization
(Bergholdt et al., 2012; Califano et al., 2012), has a total of
199-unique human pathways with 5197 unique genes/proteins
(http://www.genome.jp/kegg/pathway.html). In this integrated
network, the potential role of each gene signature in each
pathway was studied. To verify known role of these pathways
in T2DM, the PubMed was curated using the key words “type
and 2 and diabetes and insulin and (signaling or resistance or
sensitivity) and (secretion or pancreatic or islets)” in combination
with terms indicating each of these pathways. Genes interacted
with disease are involved to share functional relationships and
represent pathways of interest for the pathogenesis of insulin
resistance and T2DM.
Drug-Gene Network
In drug-gene network, we investigated for genes that interrelate
with anti diabetic-drugs using CTD (http://ctdbase.org/)
database. CTD is a source of physically curated chemical-
gene, chemical-disease and gene-disease interactions from
the literature (Davis et al., 2011). We used chemical-gene
interaction query for each gene (T2DM-related) in CTD
and accessed drugs using the default parameters. In this
interaction, drugs were directly linked with T2DM-associated
gene were sorted. We used DrugBank database to verify
the FDA-approval status of each drug in the interaction
network.
RESULTS
Gene Expression Data and Normalization
We used human GEO dataset to find new drug target gene
signatures related to insulin resistance and type 2 diabetes
mellitus. The cDNA data has118-samples with 54675 genes
derived from the study design of mRNA expression profiling of
skeletal muscle of type 2 diabetes (Gallagher et al., 2010). The
AffyBatch object comprises the size of the array 1164 × 1164
features with 54675 affyIDS. The quantile normalization of
the probes showed quality metrics of the normalized distances
between arrays of entire DNA chip. Patterns in this metrics
revealed clustering of the arrays either because of intended
biological or unintended experimental factors (Figure 2). The
individual probes in a probe set was organized by location relative
to the 5′-end of the targeted RNA molecule. The 3′/5′ intensity
gradient has been shown to depend on the degree of competitive
binding of specific and of non-specific targets to a particular
probe. Poor RNA quality is related with a reduced amount of
RNA quantity hybridized to the array followed by a declined
total signal level. Increasing degrees of saturation decrease the
3′/5′ intensity gradient, and we found that short probe sets
near the 3′-end of the transcripts (Figure 3). The function
summary AffyRNAdeg produced a single summary-statistic for
each array in the batch (Supplementary Table 1) indicating an
assessment of the severity of RNA-degradation and significance
level.
Identifying Differentially Expressed Genes
(DEGS) and Cross-Validation
An automatic process was used to execute pair-wise comparison
between biologically-comparable groups that found a total
of 50 DEGs (all down regulated) from expression profiling
in the skeletal muscle of normal (NGT), glucose intolerant
(IGT) and type 2 diabetic (T2DM) samples (Supplementary
Table 2). For reliable results and verification of differential
analysis, we let off any sub-group without repetition from the
comparisons and the “cv.glm” function of generalized linear
models estimated the cross validation prediction error. The
dispersion criterion for Gaussian is 0.088314 which shows the
confidence level (Table 1). We obtained the same delta value of
0.08847 with K-folds estimation as we used the LOOCV method
(during raw cross validation and then during adjusted cross
validation). The significant codes (0.1, 0.01, 0.001, and 0.05) with
minimum deviance residuals indicated the quality of differential
analysis.
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Identifying T2DM Associated Genes and
Cluster Analysis
Among differentially expressed genes, 9 T2DM-related genes
were identified including: ZEB1, USP16, IL6ST, ASPH,
Eif4g1, RBL2, MEF2A, vapB, and SOS2 after disease-gene
interaction using CTD, PubMed, OMIM, MeSH and PMC
databases. The role of each gene in T2DM was curated and
counted (Figure 4). To show the relationship between these
differentially expressed genes and T2DM, we estimated the
“similarity” between disease-gene interaction by calculating
the Absolute Pearson correlation cluster analysis from two
profiles (Figure 5). Clustering analysis has recognized to be
helpful to understand gene function, gene regulation, and
cellular processes. The genetic expression profiling of skeletal
muscle of normal (NGT) is distinguished from the glucose
intolerant (IGT) and type 2 diabetic (DM) samples, signifying
that obvious differences existed among these cases (treated and
untreated).
Gene Network Analysis and Finding Gene
Signatures
In genetic network of differentially expressed genes, total of
885 nodes and 959 edges were retrieved from STRING and
HAPPI databases (Figure 6). This entire network showed
that T2DM-related DEGs were found to interact with other
functionally related potential genes that are contributing
to a disease phenotype. We identified 31-gene signatures
associated with T2DM by disease-gene mapping using CTD,
PubMed, OMIM, MeSH and PMC databases (Figure 7A).
In the molecular sub-network (462-nodes and 457-edges),
these 31-genes were first-order neighbors of the T2DM-
related seeder genes. These gene signatures were found
to interact with T2DM-related differentially expressed
seeder genes: IL6RB_HUMAN (IL6ST), SOS2_HUMAN
(SOS2), MEF2A_HUMAN (MEF2A), ZEB1_HUMAN
(ZEB1), IF4G1_HUMAN (Eif4g1), RBL2_HUMAN (RBL2),
ASPH_HUMAN (ASPH), VAPB_HUMAN (vapB), and
UBP16_HUMAN (USP16) (Figure 7B). Using network topology
to rank these gene signatures, we identified that among 31-
gene signatures, 13 genes had significant connection with
IL6RB_HUMAN (IL6ST) seeder gene followed by the 6 with
SOS2_HUMAN (SOS2) gene (Figure 7C). In gene ontology
(GO) enrichment-based analysis, we selected genes in profile
based on fold change combine a p-value cut-off (<0.05) which
is more consistent selection than those merely based on p-value
or fold-change alone. These genes are significantly enriched
with MAPK cascade, Insulin signaling pathway, interleukin-
6-mediated signaling, insulin receptor signaling, JAK-STAT
cascade, regulation of insulin secretion and triglyceride
metabolic process (Table 2). The significant transcript factors
for T2DM were observed including SP1, NFIC, ZFP161, FOS,
JUND, and JUNB (Figure 8). We observed transcript abundance
in these genes with known T2DM (SP1 80.6%).
FIGURE 5 | Cluster analysis of diabetes type 2-related differentialy expressed genes with 1-Absolute Pearson correlation (Binning method: Equal
width). Blue corresponds to small distance and Red to large distance. Lines indicate the clusters boundaries in the level of the tree.
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FIGURE 6 | Genetic network of 50-differentially expressed genes with 885 nodes and 959 edges. Red nodes representing “T2DM” genes while blue nodes
are non-diabetic differentially expressed genes.
Classifying T2DM-Gene Specific MiRNAs
Targets
MicroRNAs are considered to be important regulators of
genes and have already been involved in a growing number
of diseases. The computational algorithms (miRanda,
mirSVR) predicted T2DM-gene specific multiple miRNA
targets including hsa-miR-7, hsa-miR-486-5p, hsa-miR-
148b, hsa-miR-140-5p, and hsa-miR-7. The dysregulation of
these genes are associated with insulin resistance and type 2
diabetes mellitus. The genes sirt1, pdgfra, shc1, sos, and sos1
predicted 73, 76, 76, 82, and 82 miRNAs hits respectively
(Table 3).
Pathways Model with Putative T2DM
Associated Genes
Genes in T2DM-interactome was studied for pathways modeling
which revealed that several pathways are involved in T2DM-
pathophysiology. Other than insulin-signaling and T2DM
pathway that relates to both insulin secretion and insulin-
signaling, the other pathways such as JAK-STAT, MAPK, TGF,
Toll-like receptor, p53 and mTOR, adipocytokine, FOXO, PPAR,
and P13-AKT signaling pathways have all been connected in
T2DM (Figure 9A). Although we found enrichment of several
pathways associated with gene signatures, insulin signaling was
obvious in over-represented pathways model. Collectively, our
analysis determined 11-signaling pathways as a connecting-link
between gene signatures in insulin resistance and T2DM. The
database was curated to verify the known role of these pathways
in T2DM. In this study, we found 8-gene signatures associated
with JAK-STAT signaling pathways followed by the FOXO and
MAPK pathways (7 and 6-genes respectively) (Figure 9B).
Finding Potential Anti-T2DM Drug Targets
in DG-Network
We used a toxicogenomic approach for drugs-genes (DG)
interaction to further explore the existing treatment and
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FIGURE 7 | Molecular Sub-network analysis (A) gene Mapping and role of gene signatures in T2DM was curated and counted in CTD, PMC, PubMed, OMIM, and
MeSH databases (B) molecular sub-network (462 nodes and 457 edges) of T2DM-related differentially expressed seeder genes interacted with T2DM-related gene
signatures. The interaction is highlighed with red color (C) total number of gene signatures associated with each T2DM-related differentially expressed seeder genes.
better understanding of disease etiology. Gene that interact
with antidiabetic drugs metformin, mipyridamole, leptin,
troglitazone, pioglitazone, acarbose, decitabine, tolbutamide,
decitabine, gliclazide, vildagliptin, sitagliptin, estradiol,
saxagliptin, liraglutide, exenatide, and few others were identified
using the publicly available CTD database. Among them, we
found 13-FDA approved drugs. In this interaction, we identified
18-genes as potential drug targets (Figure 10) involved in type 2
diabetes mellitus.
DISCUSSION
The current study signifies the important relationship of genetic
variation with gene expression and functional role of these
genes in disease. The analyses provide a list of potential
T2DM genes based upon differential expression in skeletal
muscles, interaction with known T2DM-related gene signatures
and correlation with metabolic pathways. The expression
profiling of these genes is indicating the obvious differences in
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TABLE 2 | Gene Ontology and enriched pathways in T2DM-related genes signatures.
Term P-Value Fold enrichment FDR
GO:0007167∼enzyme linked receptor protein signaling pathway 2.03E-18 21.69175627 3.21E-15
GO:0007169∼transmembrane tyrosine kinase signaling pathway 8.32E-13 23.37788018 1.31E-09
GO:0010604∼positive regulation of protein metabolic process 5.96E-11 8.147250348 9.41E-08
GO:0042127∼regulation of cell proliferation 2.76E-10 8.317416076 4.36E-07
IPR001245:Tyrosine protein kinase 1.30E-09 8.47353586 2.05E-06
GO:0007242∼intracellular signaling cascade 7.14E-09 8.505295739 1.13E-05
GO:0007166∼cell surface receptor linked signal transduction 3.98E-08 33.88927637 4.41E-05
GO:0016310∼phosphorylation 4.08E-08 4.232202447 6.45E-05
GO:0045597∼positive regulation of cell differentiation 4.81E-07 9.370036278 5.72E-04
hsa05200:Pathways in cancer 5.77E-07 9.148576452 9.12E-04
GO:0009725∼response to hormone stimulus 8.92E-07 64.63373656 0.001027
GO:0007259∼JAK-STAT cascade 1.49E-06 18.40418261 0.00171
hsa04630:Jak-STAT signaling pathway 3.01E-06 47.43338008 0.004748
GO:0042981∼regulation of apoptosis 3.91E-06 15.56769569 0.004502
GO:0019221∼cytokine-mediated signaling pathway 1.45E-05 32.08728653 0.022906
IPR013019:MAD homology, MH1 8.69E-05 5.768124204 0.103221
IPR001132:SMAD domain, 8.72E-05 201.5201613 0.096554
h_egfPathway: EGF Signaling Pathway 6.42E-04 76.37058824 0.7883
GO:0012501∼programmed cell death 0.001802 5.074268567 2.809631
hsa04910:Insulin signaling pathway 0.002675 37.74786043 3.133987
GO:0046425∼regulation of JAK-STAT cascade 0.002842 7.847222222 2.749384
GO:0031625∼ubiquitin protein ligase binding 0.002858 36.3655914 4.421405
GO:0008286∼insulin receptor signaling pathway 0.002896 36.06388889 3.511908
h_TPOPathway: TPO Signaling Pathway 0.003845 2.49245367 5.905743
GO:0070102∼interleukin-6-mediated signaling pathway 0.006558 293.8390805 7.220592
hsa04350:TGF-beta signaling pathway 0.006687 288.5111111 7.938695
GO:0000165∼MAPKKK cascade 0.007536 4.626011627 11.26526
GO:0060397∼JAK-STAT in growth hormone signaling pathway 0.008842 218.1935484 13.0922
hsa04062:Chemokine signaling pathway 0.008973 214.9548387 9.502942
IPR013801:STAT transcription factor, DNA-binding 0.012540 153.5391705 13.04699
GO:0005138∼interleukin-6 receptor binding 0.015483 15.2228057 21.84943
GO:0007183∼SMAD protein complex assembly 0.017556 6.834677419 15.92934
h_il3Pathway:IL 3 signaling pathway 0.020837 2.432792005 22.86529
hsa04920: Adipocytokine signaling pathway 0.036196 5.273560082 44.15
h_aktPathway: AKT Signaling Pathway 0.050395 7.838181818 44.1915
GO:0031016∼pancreas development 0.073471 6.480996487 70.05124
GO:0006916∼anti-apoptosis 0.075371 6.386152636 71.00653
GO:0042102∼positive regulation of T cell proliferation 0.076007 6.355151895 71.32031
GO:0050796∼regulation of insulin secretion 0.083053 22.37882548 74.58724
GO:0006641∼triglyceride metabolic process 0.087090 5.870678432 76.29865
skeletal muscle of normal samples from the glucose intolerant
(IGT) and type 2 diabetic (DM) samples (Gallagher et al.,
2010).
We found 50 down regulated differentially expressed genes
that showed the interaction with known T2DM-associated genes
(ZEB1, USP16, IL6ST, ASPH, Eif4g1, RBL2, MEF2A, vapB,
and SOS2) after mapping in databases. The dysregulation and
functional aberration of these differential genes has also been
studied (Baxter, 2008; Pihlajamäki et al., 2009; Jewell et al., 2010;
Jowett et al., 2010; Nitert et al., 2012; Reddy et al., 2012; Chow
et al., 2014; Liew et al., 2014; Neglia et al., 2014) in type 2 diabetes
progression. The T2DM linked genes including ZEB1, USP16,
IL6ST, ASPH, Eif4g1, RBL2, MEF2A, vapB, and SOS2 effect
on pancreatic β-cells, peripheral glucose uptake in muscles, the
secretion of multiple cytokines, β-cell gene expression, islet cells,
β-cells chromatin and proliferation attenuation (Baxter, 2008;
Jowett et al., 2010; Nitert et al., 2012; Chow et al., 2014; Liew et al.,
2014). The genetic networks extended the analysis of transcripts
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FIGURE 8 | Transcription factors for T2DM-related gene signatures involved to alter gene expression in a host cell to promote insulin resistance and
pathogenesis.
to predict interactive gene signatures that have role in diabetes
pathophysiology. The molecular sub-network revealed the direct
interaction of functionally related 31-gene signatures with seeder
genes. In this interaction, we found significant number of gene
signatures (13-genes) in connection with T2DM-related IL6ST
seeder gene. The variant role of family of IL6-genes has been
studied in type 2 diabetes (Chow et al., 2014). Similarly, we
observed that SOS2 was another seeder gene that was linked with
SRC, INSRR, EGFR, FGFR1, PGFRA and PGFRB gene signatures
that were significantly associated with insulin resistance and type
2 diabetes (Davidson et al., 2012; Singh and Kakkar, 2013; Zheng
et al., 2013; Li et al., 2015). These observations indicated that the
aberration in DEGs expression precede the disturbances in gene
signatures ultimately causes type 2 diabetes. The curation and
mapping of these gene signatures with T2DM further verified this
relationship.
To gain insight into the direction of systems biology,
these genes are considerably enriched with Insulin signaling
pathway, insulin receptor signaling, interleukin-6-mediated
signaling, MAPK cascade, JAK-STAT cascade, regulation of
insulin secretion and triglyceride metabolic process. We find
that T2DM-gene signatures identified in enrichment analysis
can elucidate disease conditions when the interlinked genes
are taken together with their protein and functional level
interactors (Lee et al., 2011; Lakshmanan et al., 2012; Chow
et al., 2014; Ma L. et al., 2015; Ma W. et al., 2015). These
signaling pathways contained the significant gene regulatory
network of transcript factors families for type 2 diabetes
including SP1, NFIC, ZFP161, and FOS, JUND, JUNB. The
pathways modeling and integrative network based analysis of
gene signatures revealed 11-signaling pathways including insulin
secretion, insulin signaling, JAK-STAT, MAPK, TGF, Toll-like
receptor, p53 and mTOR, adipocytokine, FOXO, PPAR, and P13-
AKT signaling pathways have all been connected in T2DM.
Recent reports and literature search indicated our genomic,
interactomic, and toxicogenomic evidence to converge on vital
pathways including insulin signaling, JAK-STAT signaling, P13-
AKT signaling, FOXO signaling, and TGF-beta signaling, the
vital pathway involved to play a critical role in pancreatic islets
maturity and function, and insulin secretion (Jain et al., 2013).
Collectively, we find that genes link directly to insulin secretion
and indirectly, through communication with other genes, to
insulin resistance and T2DM.
Gene-drug interactions of great interest because such
association can not only expressively improve our understanding
of disease pathophysiology, but also are helpful in drug discovery
processes. The disease related genes-drugs association network
can be improved by data mining and biomedical linkages (Chen
et al., 2008). Our toxicogenomic-based approach supported
this analysis. In this network, 13-FDA approved and few
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TABLE 3 | miRNA targets related to T2DM-related gene signatures.
Uniprot_ID Gene_Name microRNA mirSVR score Nuclei mapped to alignments Total MiRNA hits Structure of predicted duplex
INSI1_HUMAN INSIG1 hsa-miR-7 −0.1826 170 51 ugUUGUUUUA-GUGA–UCAGAAGGu
INSRR_HUMAN INSRR hsa-miR-132 −1.0038 74 5 gcugguaccGACAUCUGACAAu
SOCS_HUMAN Socs hsa-miR-324-5p −0.5384 17 24 ugugguuaCGGGAU–CCCCUACGc
PGFRB_HUMAN Pdgfrb hsa-miR-24 −0.3169 217 32 gacaaGGACGACU-UGACUCGGu
STAT_HUMAN STAT hsa-miR-421 −0.1519 111 17 cgcgGGUUAA-UUAC—AGACAACUa
EGFR_HUMAN egfr hsa-miR-370 −0.1112 46 34 ugGUCCAAGGU-GGGGUCGUCCg
SMAD7_HUMAN SMAD7 hsa-miR-15b −1.1638 43 62 acaUUUGGUACUACACGACGAu
SMAD3_HUMAN SMAD3 hsa-miR-490-3p −0.1643 1086 19 gucgUACCUC-AGGAGGUCCAAc
UBP_HUMAN USP hsa-miR-410 −0.2122 112 18 uguccgguagacacAAUAUAa
JAK3_HUMAN JAK hsa-miR-139-5p −0.1403 143 42 gaccucugUGCACGUGACAUCu
SRC_HUMAN Src hsa-miR-491-5p −0.2503 350 18 ggAGU-ACCUUCCCAAGGGGUGa
UBP16_HUMAN USP16 hsa-miR-520a-3p −0.8179 1 27 ugucagguuucccUUCGUGAAa
SOS2_HUMAN SOS hsa-miR-148b −0.2544 45 82 uguuucaagACAUCACGUGACu
JAK2_HUMAN Jak2 hsa-miR-133a −0.1218 7 47 gucgaccaacuucccCUGGUUu
SMAD2_HUMAN SMAD2 hsa-miR-486-5p −0.1007 288 2 gagcccCGUCGA-GU-CAUGUCCu
STAT3_HUMAN Stat3 hsa-miR-544 −0.4626 5 47 cuugaacGAUUUUUACGUCUUa
MK14_HUMAN Mapk14 hsa-miR-421 −0.2044 1 35 cgcGGGUUAAUUAC-AGACAACUa
PGFRA_HUMAN pdgfra hsa-miR-140-5p −0.3169 46 76 gauGGUAUCCCAUUUUGGUGAc
STAT4_HUMAN STAT4 hsa-miR-132 −1.0501 37 15 gcuggUACCGACAUCUGACAAu
SHC1_HUMAN SHC1 hsa-miR-140-5p −0.3169 46 76 gauGGUAUCCCAUUUUGGUGAc
SOS1_HUMAN SOS1 hsa-miR-148b −0.2544 45 82 uguuucaagACACUACGUGACu
FOXO4_HUMAN FOXO4 hsa-miR-149 −0.1391 23 24 cccucacuUCUGUGCCUCGGUCu
SQSTM_HUMAN sqstm1 hsa-miR-193a-3p −0.1698 68 36 ugacCCUGAAACAU–CCGGUCAa
FOXO3_HUMAN FOXO3 hsa-miR-599 −0.1021 34 49 gaugauuuuguacCUUCGUGAAu
SOCS3_HUMAN socs3 hsa-miR-551a −0.4552 8 28 acCUUUGGUUCUC–ACCCAGCg
IL6_HUMAN IL6 hsa-miR-365 −0.1918 16 28 uauucCUAAAAAUCCCCGUAAu
FGFR1_HUMAN Fgfr1 hsa-miR-133a −0.1491 241 30 gucgaccaacuuccCCUGGUUu
FOXO1_HUMAN foxo1 hsa-miR-370 −0.4792 32 60 ugGUCCAAGGUGGGGUCGUCCg
STX1A_HUMAN STX1A hsa-miR-491-5p −0.2032 380 21 ggaguaccuUCCCAAGGGGUGa
IF4E_HUMAN eif4e hsa-miR-150 −0.4746 38 62 gugaccauGUUCCCAACCCUCu
JAK1_HUMAN JAK1 hsa-miR-139-5p −0.1403 143 42 gaccucugUGCACGUGACAUCu
ZEB1_HUMAN ZEB1 hsa-miR-217 −0.977 219 62 agGUUAGUCAAGGACUACGUCAu
IL6RB_HUMAN IL6ST hsa-miR-873 −0.6274 1 10 uccUCUGAGUGUUCAAGGACg
ASPH_HUMAN asph hsa-miR-204 −0.4606 142 52 uccGUAUCCUACUGUUUCCCUu
RBL2_HUMAN RBL2 hsa-miR-335 −0.1191 1 47 uguaaaaagcaauaacGAGAACu
SIR1_HUMAN SIRT1 hsa-miR-486-5p −1.1526 2 73 gagccccguCGAGU-CAUGUCCu
FIGURE 9 | Pathway analysis (A) integrated genome to phenome scale signaling pathways involved in insulin resistance and T2DM. Gene signatures were mapped
on to KEGG pathway for signaling and metabolic reconstruction (B) distribution of T2DM-related gene signatures in associated pathway network.
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FIGURE 10 | Drug–Gene network (DG-network). The DG-network is generated between the reported drugs and their target gene signatures (55-nodes and
63-edges). Circles and rectangles correspond to target genes and drugs, respectively. A dotted link is placed between a drug and a target node if the gene is a known
target of that drug while solid link denotes the potential drug targets. Color codes are given in the legend. DrugBank_ID has been shown for these drugs. The
drugs-gene signature assocaition was curated using PMC, CTD, and Drug Bank databases.
non-approved drugs were associated with T2DM-related genes
leaving the 18-genes as potential drug targets. All drugs are FDA
approved except troglitazone which has been withdrawn from the
market due to its idiosyncratic reaction leading to drug-induced
hepatitis. However resveratrol and leptin are FDA investigational
drugs and curcumin is non-approved drug. More importantly,
this network proposes many testable assumptions with potential
of great success, though the real achievement can only be justified
by experimental studies.
In conclusion, gene expressionmicroarray studies have greatly
improved our knowledge of genetic mechanisms of human
diseases. Systems biology analysis of cDNA data helped us to
find T2DM-connected genes as alternative drug targets using
interactomic and toxicogenomic data that led us to link with
vital metabolic and signaling pathways involved in disease
pathophysiology. Our simple and integrated steps are helpful
in revealing genome to phenome association in diabetes and
finding potential drug targets for type 2 diabetes. Therefore this
approach will support to understand the genetic basis of complex
phenotypes. These findings can provide a valuable framework
for developing diagnostic biomarkers and treatment strategies.
However, further molecular studies can be designed to validate
the role of these genes in T2DM for effective treatment.
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